Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study

Background: The phase 3, prospective PROPEL study demonstrated that pharmacokinetic (PK)-guided prophylaxis targeting elevated factor VIII (FVIII) troughs in patients with hemophilia A resulted in lower annualized bleeding rates (ABRs) and a higher proportion of patients experiencing zero bleeds in...

Full description

Bibliographic Details
Main Authors: Carmen Escuriola-Ettingshausen, Robert Klamroth, Miguel Escobar, Oleksandra Stasyshyn, Srilatha Tangada, Werner Engl, Ivan Honauer, Hye-Youn Lee, Pratima Chowdary, Jerzy Windyga
Format: Article
Language:English
Published: SAGE Publishing 2023-06-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207231178596

Internet

https://doi.org/10.1177/20406207231178596

Similar Items